News round-up for 25-29 August by DDW Senior Digital Content Editor Diana Turner.

There have been some significant regulatory decisions this week, including a new orphan designation from the EMA and the FDA go-ahead for Rocket Pharma’s paused gene therapy trial.

The top stories:

Graft-versus-host treatment gets EMA orphan drug designation

The European Medicines Agency (EMA) has granted orphan drug designation to ReAlta’s RLS-0071 (pegtarazimod) for the treatment of graft-versus-host disease (GvHD).

Read more…

Health Canada extends approval of Bayer’s darolutamide

Health Canada has granted marketing authorisation for Bayer’s oral androgen receptor inhibitor (ARi) Nubeqa (darolutamide) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).

Read more…

FDA lifts hold on Rocket Pharma’s Phase II trial of RP-A501

The US Food and Drug Administration (FDA) has lifted the clinical hold on Rocket Pharmaceuticals’ pivotal Phase II trial of RP-A501 for the treatment of Danon disease.

Read more…

Cereno Scientific granted FDA fast track designation for CS1

The US Food and Drug Administration (FDA) has granted Fast Track designation to Cereno Scientific’s lead programme, CS1, for the treatment of pulmonary arterial hypertension (PAH).

Read more…